Brief: Inmune Bio Reports Key Findings From Phase 2 Mindful Trial Of Xpro™ In Early Alzheimer’S Disease
30/06/2025 12:44
INmune Bio Inc INMB.O: INMUNE BIO REPORTS KEY FINDINGS FROM PHASE 2 MINDFUL TRIAL OF XPRO™ IN EARLY ALZHEIMER’S DISEASE Source text: ID:nGNE6NtP8D Further company coverage: INMB.O
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview